Endothelial leukocyte adhesion molecule-1 (ELAM-1) is one member of the selectin family which is expressed on endothelial cells activated by cytokines and involved in the adhesion to neutrophils. ELAM-1 is involved in the leukocyte rolling phenomenon that occurs at the initial stage of inflammation and is also involved in myocardial ischemiareperfusion 13. 14)
It is reported that inflammation can be decreased in an ischemia-reperfusion injury skin flap model by using antibodies to the adhesion molecules ICAM-1 (intercellular adhesion molecule-1) and LECAM-1 (leukocyte endothelial cell adhesion molecule-1)1o. u). In this study we investigated the skin flap survival ratio and tissue changes when administrating anti-ELAM-1 monoclonal antibodies using this ischemia-reperfusion injury skin flap model. 
Ischemic interval
The ischemic interval was 9 hours, or 5 minutes for the sham group.
Antibody administration
An anti-ELAM-1 antibody (0.20 mg / kg) (AF977, R & D Systems Inc., Minneapolis, MN, USA) was administered by intravenous injection to the caudal vein 15 minutes before releasing the clamp. Sterilized saline at the same dose was administered in the same manner as the control.
Experimental groups
An anti-ELAM-1 antibody treatment group (n =10) and a physiological saline control (n = 10) were observed over 7 days. A skin flap was elevated in the same manner in the sham group (n = 5), but the clamp was released after 5 minutes. The animals were euthanized at the end of the 7-day observation by an overdose of anesthesia and histological examination of the skin flaps was conducted (Fig. 2) .
Method o f evaluation
Skin flaps were evaluated by macroscopic observation and histological analysis. 1) Skin flap survival area ratio The area ratio of the skin flap survival and necrotic regions was calculated by tracing based on the template method of Morris et alto obtain the survival area ratio 15) 2) Histological examination Tissue samples were stained with hematoxylin-eosin and observed for characteristics of inflammation, the extent of infammation and for the condition within blood vessels. 6 . Statistical analysis 
Skin flap survival area ratio
Non-comparative analysis of the treatment group administered anti-ELAM-1 antibody and the control group administered physiological saline was conducted.
Comparison of macroscopic findings showed that skin flap survival in the treatment group was good with skin flap morphology and color similar to the sham group.
However, in the control group, skin flaps showed severe inflammation accompanied by partial necrosis (Fig. 3) . 
Histological examination
Although characteristics of inflammation were observed in the treatment group, the degree of inflammatory cell infiltration and edema was comparatively mild, the intravascular lumen was intact and tissue structure close to that of the sham group. In the control group, however, inflammatory cell infiltration, edema and necrosis were observed, showing markedly different findings from the treatment group (Fig. 5) . Animals in the sham-operated group were ischemic for 5 minutes. The viable area treated with monoclonal antibody to ELAM-1 was significantly higher than the viable area of the flap in the control group. Discussion ELAM-1 is also known as E-selectin or CD62E 13,14) Its molecular structure is that of a type I membrane glycoprotem with an extracellular N-terminal region consisting of a lectin domain, EGF (epidermal growth factor) domain and 6 complement regulatory protein (CRP) domains, a membrane-spanning segment and an intracellular domain containing the C-terminal (Fig. 6) The importance of ELAM-1 is mainly its involvement in the rolling of neutrophils, and some lymphocytes, to activated vascular endothelium and the subsequent transition to adhesion of these cells 18) . Selectins bind weakly to its ligand on a partner cell. As a result a stress gradient is produced between selectin and blood flow and leukocytes roll over the vascular endothelium. Following selectin shedding, chemokines produced by vascular endothelial cells activate the leukocytes, which bind to integrin-mediated intercellular adhesion molecule-1 (ICAM-1).
This mediates stronger intercellular adhesion. Finally the leukocytes pass through the intercellular space and infiltrate the extravascular inflammation site (Fig. 7)19) . Ischemia-reperfusion injury is an inflammatory reaction and therefore involves the events described above. An experimental model of ischemia-reperfusion injury using skin flaps was used to clarify this mechanism5, 11) In this model, administration of anti-ICAM-1 monoclonal antibodies markedly suppressed the effects of inflammation 5) .
In this study, inflammation was markedly suppressed by monoclonal antibodies against ELAM-1. It is surmised that administration of anti-ELAM-1 antibody inhibits the adhesion of activated leukocytes to vascular endothelium during the initial stages of inflammation. Thus, the subsequent rolling phenomenon is blocked and inflammation is attenuated (Fig. 8) .
Platelet activating factor (PAF), IL-6 and tumor necrosis factor (TNF) are induced after reperfusion in ischemia-reperfusion injuries and the destruction of tissue progresses 20) . Administration of PAF antagonists 6) or tacrolimus7) reduces the effects of ischemiareperfusion injury. Several mechanisms of action have been suggested7). These include inhibition of superoxide radical formation by neutrophils, inhibition of mediators induced by neutrophils such as TNF and LTB4, inhibition of TNF or IL-6 induction by reperfusion, and weakening of the binding interaction between neutrophils and vascular endothelial cells by inhibition of CD11 / CD18. It is further reported that anti-LECAM-1 antibody significantly reduces inflammatory effects in skin flaps 10) Recently the usefulness of ELAM-1 for inflammatory disorders, and platelet coagulationrelated disorders and as a blood marker for vascular endothelial damage has been investigated because its expression is accompanied by the activation of leukocytes, platelets and vascular endothelium due to cytokine or antigen stimulation 19) . Further, cancer cells adhering to vascular endothelium by ELAM-1 are thought to metastasize and to be deeply involved in blood-borne metastasis 19, 22) . In the future it may be possible to apply an index of skin flap necrosis by measuring serum ELAM-1 in an ischemia-perfusion injury skin flap 23, 24) .
In the present experiment a significant reduction in inflammatory effects in skin flaps was observed in the anti-ELAM-1 antibody treatment group in an ischemia-reperfusion injury skin flap model. Further experimental research will be needed for full elucidation of the function of ELAM-1 and the mechanism of action of its monoclonal antibody. However, the marked attenuating effect on inflammation obtained in this research suggests that administration of the monoclonal antibody to ELAM-1 is potentially an effective technique to prevent partial necrosis of skin flaps.
